DraftKings Becomes an Official Partner of the Detroit Pistons

Deal Includes Daily Fantasy, Sports Betting and iGaming Partnerships

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) — The Detroit Pistons and DraftKings Inc. (Nasdaq: DKNG) today announced a new deal, making the sports technology and entertainment company the exclusive Official Daily Fantasy Sports Partner, as well as an Official Sports Betting and iGaming Partner of the NBA team. In addition to access to Pistons trademarks and logos, the deal includes DraftKings-branded courtside LED signage and in-game basket pad branding. The agreement comes as DraftKings prepares to launch mobile sports betting and online gaming in the state of Michigan, pending licensure and the receipt of necessary regulatory approvals.

“As our first professional team activation in the state of Michigan, we are thrilled to join forces with the Detroit Pistons ahead of our pending market introduction,” said Ezra Kucharz, Chief Business Officer, DraftKings. “This deal deepens our relationship with a prominent local team to facilitate more immersive fan experiences, both for Michiganders familiar with regulated gaming products as well as newcomers to the space.”

Pistons fans will also have the opportunity to compete for a variety of experiential prizes, including a Pistons away game trip, a ‘Court of Dreams’ group event held at Little Caesars Arena, ‘Piston for the Day’ VIP experience. As part of the VIP package, individuals will have the opportunity sign an honorary Pistons contract to participate in a private, in-stadium shootaround, tour the official lockerroom facilities, and sit courtside at a Pistons regular season home game.

“We appreciate the partnership-minded and collaborative approach that DraftKings brings to the table,” said Mike Zavodsky, Chief Business Officer, Detroit Pistons. “We look forward to utilizing our platform to help DraftKings grow their presence and connectivity to Pistons fans and to the greater Metro Detroit communities.”

Fans can participate in the free-to-play Detroit Pistons popularity pool by downloading DraftKings’ Sportsbook, Casino, and Daily Fantasy products via iOS and Android here. Additionally, new DraftKings Sportsbook and Casino customers in Michigan can claim a free $200 bonus by registering here today.

About The Detroit Pistons
Since their arrival in 1957, the Detroit Pistons have become one of the most storied franchises in the NBA. With over 2,300 regular-season and playoff victories, the club has celebrated three NBA Championships (1989, 1990, 2004), five NBA Finals appearances (1988, 1989, 1990, 2004, 2005) and 11 Eastern Conference Finals appearances. In October 2019, the club opened the new Henry Ford Detroit Pistons Performance Center located in the New Center area, a campus that serves as the organization’s practice facility and corporate headquarters. Since its purchase by Michigan native Tom Gores in 2011, the organization has focused on operating as a community asset while promoting a culture of innovation and industry-leading thought.

About DraftKings

DraftKings Inc. (Nasdaq: DKNG) is a digital sports entertainment and gaming company created to fuel the competitive spirits of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings is a multi-channel provider of sports betting and gaming technologies, powering sports and gaming entertainment for 50+ operators across more than 15 regulated U.S. and global markets, including Arkansas and Oregon in the U.S. DraftKings’ Sportsbook offers mobile and retail betting for major U.S. and international sports and operates in the United States pursuant to regulations in Colorado, Illinois, Indiana, Iowa, Mississippi, New Hampshire, New Jersey, New York, Pennsylvania, Tennessee and West Virginia. DraftKings’ daily fantasy sports product is available in 8 countries internationally with 15 distinct sports categories. DraftKings is the official daily fantasy partner of the NFL, MLB and the PGA TOUR as well as an authorized gaming operator of the NBA and MLB and an official betting operator of the PGA TOUR.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside DraftKings’ control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see DraftKings’ Securities and Exchange Commission filings. DraftKings does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact

[email protected]

@draftkingsnews



Former Google Fiber VP Jill Szuchmacher joins Ting Internet as Chief Strategy Officer and EVP Networks

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Ting Internet, a top-rated fiber-optic Internet Service Provider (ISP) and division of Tucows (NASDAQ: TCX, TSX: TC), is proud to welcome Jill Szuchmacher and her proven Internet leadership to the team as Chief Strategy Officer and Executive Vice-President Networks for Ting Internet.

Szuchmacher joins Ting Internet after executing in high-profile roles, most recently as Vice President of Operations at Google Fiber, where she led strategy, planning, training and analytics for build and field operations. As CSO and EVP Networks for Ting Internet, she will lead a world-class team to drive the Ting Internet business forward.

“This is a key leadership role for Ting Internet and for Tucows,” said Elliot Noss, CEO of Tucows. “The need for fast, reliable Internet access has never been more apparent. 2020 squeezed years of latent change into months. Rapid adoption is a trend we see continuing as people and businesses rely more and more on the Internet to connect. Jill Szuchmacher is precisely the leader we need to ramp and scale Ting Internet to meet these opportunities and navigate the multi-generational transition from coax and copper to fiber.”

In prior roles at Google, Szuchmacher served as Director of Business Development for a range of media-focused products, working with product and engineering teams to forge partnerships and relationships for new and emerging products. Szuchmacher is a graduate of Harvard Business School and brings a wealth of experience—from MTV to Scholastic, from startups to multinational corporations.

“I’ve followed the good work Ting Internet is doing to bring next generation Internet access to people and businesses in towns and cities all across the US. I’m excited to lead on strategy and deployment as we work together to achieve the next level of impact and scale for Ting Internet,” said Jill Szuchmacher, CSO and EVP Networks, Ting Internet. “I look forward to working with the great team at Ting and partnering with communities and local governments to drive toward the shared goal of better Internet access for all.”

Szuchmacher is based in New York where she will work with colleagues at Ting Internet’s offices in Toronto, across the U.S. and around the world.

Jill Szuchmacher, Elliot Noss and key members of the Tucows executive team are available for interview and comment.

About Ting Internet

Ting Internet provides Crazy Fast Fiber Internet® in select US towns and cities. Ting Internet is committed to net neutrality and the Open Internet. More than that, Ting Internet is committed to being a part of improving the communities it serves by supporting and championing local good works. Ting Internet sponsors local programs, events, foundations, festivals, charities, and public services everywhere we go, investing in the future of the towns we serve.

About Tucows

Tucows is a provider of network access, mobile technology services, domain names and other Internet services. Ting Internet (https://ting.com/internet) delivers fixed fiber Internet access with outstanding customer support. Tucows’ mobile services enabler (MSE) platform provides network access, provisioning and billing services for mobile virtual network operators (MVNOs). OpenSRS (https://opensrs.com), Enom (https://www.enom.com) and Ascio (https://ascio.com) combined manage approximately 25 million domain names and millions of value-added services through a global reseller network of over 36,000 web hosts and ISPs. Hover (https://hover.com) makes it easy for individuals and small businesses to manage their domain names and email addresses. More information can be found on Tucows’ corporate website (https://tucows.com).

Tucows, Ting, OpenSRS, Enom and Hover are registered trademarks of Tucows Inc. or its subsidiaries.

Press contact:

Monica Webb
647-898-9924
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3fb4eb99-8c10-4a2c-ac55-540a6d8d80a4



Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger
to
c
reate
Nasdaq-listed company focused on developing Viracta’s
precision oncology
pipeline
targeting virus-associated malignancies

Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-
positive
lymphomas expected
to begin in the first half of 2021

Leading institutional investors
commit
ted
a
total of
$
10
5
million in private
financing
s
with Viracta

Combined
company expect
ed
to have
approximately
$
1
2
0
million
cash balance
following the close of the merger

Companies
to
host conference call today
at
8
:
3
0
AM
Eastern Time

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta Therapeutics, Inc., a privately held precision oncology company targeting virus-associated malignancies, today announced they have entered into a definitive merger agreement (the “Merger Agreement”) pursuant to which Viracta will combine with Sunesis in an all-stock transaction (the “Merger”). The merged company will focus on the advancement and expansion of Viracta’s clinical stage, precision oncology pipeline targeting virus-associated malignancies, including Viracta’s lead program for the treatment of Epstein-Barr virus (EBV)-positive relapsed/refractory lymphomas. Upon completion of the Merger, the combined company will operate under the name Viracta Therapeutics, Inc. and intends to be listed on the Nasdaq Global Market under the ticker symbol “VIRX.”

Viracta recently completed a $40 million Series E Preferred Stock equity financing led by aMoon, Israel’s leading healthtech and life sciences venture fund, with participation from Taiwania Capital Management, Latterell Venture Partners, LifeSci Venture Partners and other existing investors.  

Concurrent with the execution of the Merger Agreement, Viracta entered into an agreement for the sale of common stock in a private placement with an investor syndicate of institutional accredited investors led by BVF Partners L.P., with participation from aMoon, Ridgeback Capital Management, Surveyor Capital (a Citadel company), Logos Capital, Samsara Biocapital, Sectoral Asset Management, Janus Henderson Investors, LifeSci Venture Partners, and Serrado Capital LLC, as well as other institutional investors. The private placement is expected to result in gross proceeds to Viracta of approximately $65 million prior to the close of the Merger, subject to customary conditions. Upon the close of the Merger and related financing, the total cash balance of the combined company is expected to be approximately $120 million with an expected cash runway into 2024.

Viracta’s lead program evaluates the all-oral combination of nanatinostat, its proprietary investigational drug, and valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory lymphomas. There are currently no approved therapies for EBV-associated cancers, which are responsible for over 140,000 deaths each year. Viracta’s precision oncology and biomarker-driven combination product candidate targets EBV-positive cancer cells with an inducible synthetic lethality approach. Viracta plans to initiate a registration trial for the treatment of EBV-positive lymphoma in the first half of 2021, and also plans to initiate a Phase 1b/2 trial in EBV-positive solid tumors in 2021.

“This is a transformational event for Viracta, and I am very pleased to see the company brought forward into the public market,” said Roger Pomerantz, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta. “Importantly, Viracta’s novel approach to targeting viral latency represents a completely new medical modality in the landscape of precision oncology, and today is the beginning of an important and exciting new phase in the company’s evolution. EBV-induced malignancies are a high unmet medical need area, and the patients are waiting for novel therapies.”

“After a thorough evaluation of strategic alternatives, the Board of Directors of Sunesis believes this merger is in the best interest of Sunesis’ stockholders and has the potential to deliver near- and long-term value,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “This transaction will provide the resources for the combined company to leverage Viracta’s scientific platform and pipeline to treat a range of virus-associated cancers and other serious diseases. Viracta shares our mission to develop important new targeted treatments for patients living with cancer, and we are enthusiastic about the prospect of carrying on that mission.”

Ivor Royston, M.D., President and Chief Executive Officer of Viracta added, “The merger and our private financings represent a significant step in Viracta’s growth as a late-stage development company. Our ongoing Phase 2 clinical trial for the treatment of EBV-positive lymphomas has produced encouraging efficacy and safety, and these transactions provide meaningful capital as we advance this program towards registration and expand our clinical pipeline. We look forward to building upon our clinical and corporate momentum to create shareholder and patient value, as we advance our important work to address the significant unmet needs in virus-associated malignancies.”

About the Merger

Under the terms of the Merger Agreement, pending stockholder approval of the transaction, Viracta will merge with a wholly owned subsidiary of Sunesis, and stockholders of Viracta will receive shares of newly issued Sunesis common stock. Viracta stockholders are expected to own approximately 86% and Sunesis stockholders will own approximately 14% of the combined company on a fully diluted basis using the treasury stock method. The percentage of the combined company that Sunesis stockholders will own as of the close of the Merger may be subject to adjustment based on Sunesis’ net cash.

The Merger Agreement has been unanimously approved by the Board of Directors of each company. The transaction is expected to close in the first quarter of 2021, subject to approvals by stockholders of each company and other customary closing conditions.

MTS Health Partners, L.P. is serving as the financial advisor to Sunesis, and Cooley LLP is serving as legal counsel to Sunesis. SVB Leerink LLC and Evercore Group LLC served as placement agents in Viracta’s private financings. Wilson Sonsini Goodrich & Rosati is serving as legal counsel to Viracta.

Management and Organization

The combined company will be led by Viracta’s current management team and will be headquartered in Cardiff, California. The Board of Directors is expected to consist of seven members, including six members from Viracta’s board and one member from Sunesis’ board.

Conference Call and Webcast Information

Sunesis and Viracta will host a conference call and webcast today at 8:30 a.m. Eastern Time. The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (international) and entering passcode 5742158. To access the live webcast, or the subsequent archived recording, visit the “Investors and Media – Calendar of Events” section of the Sunesis website at www.sunesis.com, or the “News/Media” section of the Viracta website at www.viracta.com. The webcast will be recorded and available for replay on the respective company’s website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer.

For additional information on Sunesis, please visit www.sunesis.com.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta’s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Additional Information about the Proposed Merger and Where to Find It

Sunesis plans to file with the SEC, and the parties plan to furnish to the security holders of Viracta and Sunesis, a Registration Statement on Form S-4, which will constitute a proxy statement/prospectus of Sunesis and will include an information statement of Viracta, in connection with the proposed Merger, whereupon the separate corporate existence of Merger Sub shall cease and Viracta shall continue as the surviving corporation of the Merger as a wholly owned subsidiary of Sunesis. The prospectus/information statement described above will contain important information about Sunesis, Viracta, the proposed Merger and related matters. Investors and security holders are urged to read the prospectus/information statement carefully when it becomes available. Investors and security holders will be able to obtain free copies of these documents, and other documents filed with the SEC, by Sunesis through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents from Sunesis by contacting Sunesis’ Investor Relations by telephone at 650-266-3784 or by going to Sunesis’ Investor Relations web page at https://ir.sunesis.com/shareholder-services/contact-ir and clicking on the link titled “SEC Filings.”

Participants in the Solicitation

The respective directors and executive officers of Sunesis and Viracta may be deemed to be participants in the solicitation of proxies and written consents from the security holders of Sunesis and Viracta, respectively, in connection with the proposed Merger. Information regarding the interests of these directors and executive officers in the transaction described herein will be included in the prospectus/information statement described above. Additional information regarding Sunesis’ directors and executive officers is included in Sunesis’ proxy statement for its Annual Meeting of Stockholders, which was filed with the SEC on April 17, 2020. This document is available from Sunesis free of charge as described in the preceding paragraph.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking Statements

This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the ability of the parties to complete the proposed Merger within the expected timing, or at all, the effects of the proposed Merger, including, but not limited to, listing on Nasdaq Global Market and estimated ownership percentages of the stockholders of each company; the closing of Viracta’s private placement of its common stock on a timely basis, or at all; Viracta’s clinical development pipeline, including without limitation, the expected timing of the registration trial for EBV-associated lymphomas and the Phase 1b/2 trial in EBV-associated solid tumors; the combined company’s expected cash forecast and runway into 2024; Viracta’s ability to leverage its platform and pipeline to treat a range of cancers and diseases; and other statements that are not historical facts.  Sunesis’ expectations and beliefs regarding these matters may not materialize. Sunesis’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks relating to the ability of the parties to consummate the proposed Merger, satisfaction of closing conditions precedent to the consummation of the proposed Merger, potential delays in consummating the Merger, and the ability of Sunesis to timely and successfully achieve the anticipated benefits of the Merger. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: risks relating to the ability of the parties to consummate the proposed Merger and the ability of Viracta to complete the private placement financing, satisfaction of closing conditions precedent to the consummation of the proposed Merger and the concurrent financing, potential delays in consummating the Merger and the concurrent financing, and the ability of Viracta to timely and successfully achieve the anticipated benefits of the Merger and the concurrent financing; Viracta’s ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta’s plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta’s planned clinical trials; the timing of the availability of data from Viracta’s clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Viracta’s product candidates; Viracta’s ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Viracta’s competitors and its industry; the impact of government laws and regulations; Viracta’s ability to protect its intellectual property position; and Viracta’s estimates regarding future expenses, capital requirements and need for additional financing following the proposed transaction.

These risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in Sunesis’ most recent filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and other documents Sunesis has filed, or will file, with the SEC, including a registration statement on Form S-4 that will include a proxy statement/prospectus, any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on Sunesis’ Investor Relations page at https://ir.sunesis.com/shareholder-services/contact-ir by clicking on the link titled “SEC Filings.”

The forward-looking statements included in this communication are made only as of the date hereof. Sunesis assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

Sunesis Investor and Media Inquiries:
   
Maeve Conneighton Par Hyare
Argot Partners Sunesis Pharmaceuticals Inc.
212-600-1902 650-266-3784
   
Viracta Investor Inquiries: Viracta Media Inquiries:
Joyce Allaire Amy Conrad
LifeSci Advisors Juniper Point

[email protected]

[email protected]
212-915-2569 858-366-3243



Event Hustler Show Taps NexTech AR Leadership for December 2 Podcast on the Role of Augmented Reality in Creating Virtual and Hybrid Events

  • President Paul Duffy and Chief Channel Officer Vivian Chan will spotlight the critical role of augmented reality in bringing virtual and hybrid events to life
  • NexTech and Techsytalk are teaming up to continue providing educational resources to the
    corporate, association and independent event planning industries
  • While virtual events have been around for a while, new and innovative aspects, including Augmented Reality, are enhancing experiences and boosting ROI upwards of 140 percent

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), a leading provider of virtual and augmented reality (AR) experience technologies and services for virtual and hybrid eCommerce, education, conferences and events today announced that NexTech President, Paul Duffy and Chief Channel Officer, Vivian Chan will be featured experts on the Event Hustler Show this upcoming December 2, 2020 at 2:00pm EST. Duffy and Chan will spotlight the growing role of AR and experience mapping in the virtual and hybrid event sector. Viewers can tune in to see the interview through the link here.

The Event Hustler Show is a video podcast hosted by the CEO of techsytalk and Liz King Events, Liz King Caruso. The Podcast features interviews with top talent from independent event management and technology companies who delve into innovations, trends and significant shifts within the events industry. The podcast reaches key decision makers for events across the globe, making it a valued resource within the event management community.

Duffy and Chan were invited to speak on the podcast following Duffy’s presentation earlier this month at techsytalk Global. The event had an international audience of more than 1,300 attendees from the corporate, association and independent event planning industries, to whom Duffy shared the success of virtual event experiences with AR. This presentation with The Event Hustler Show is one of a few upcoming projects that NexTech and Techsytalk are teaming up on to provide educational resources on the capabilities of NexTech’s Experience Platform to the international event community.

This interview will go beyond Duffy’s initial presentation, taking a deeper look at what experience design is and how pivoting to virtual and hybrid events backed by AR can help the industry transform its business and achieve success. The presentation will walk viewers through the role AR is taking in the virtual and hybrid event environment as we continue to navigate closures from the COVID-19 pandemic. Furthermore, Duffy and Chan will highlight innovative applications that companies are using AR for and the range of clients that are adopting these techniques including retail, media, higher education, healthcare, agriculture and more.

“AR is an incredible story-telling and experience marketing tool. Many event organizers come to us with questions about AR, what it can do for them and how to leverage it in virtual and hybrid events. Through this interview with The Event Hustler Show, we hope to highlight new ways that events, large and small, can utilize AR as a tool to create “Get out of your seat” moments and unique experiences,” said Vivian Chan, Chief Channel Officer of NexTech. “Virtual and hybrid events with AR have transformed the business and have provided a successful solution to hosting events during COVID-19. Event organizers need to create interactive experiences or risk losing the interest of their audience, whether it’s in the form of a virtual or hybrid event.”

“I’m excited to reconnect with Liz King Caruso and continue the conversation about how AR continues to embed itself within the event management industry. Techsytalk and the Event Hustler Show hold the ear of key decision makers in the events sector, many of whom have to prepare for the unknown that is 2021. The emotional connection people make with brands through sight, sound and motion are undeniable. We’ve seen it with television and video. But as technology continues to advance, customer experiences will be tied to immersing the consumer with the brand experience,” said Paul Duffy, President of NexTech AR, “Virtual and hybrid events are the future and we’ve created a portfolio of AR technologies with proven performance in boosting attendance, engagement and creating customized experiences. AR is a solution on how to design, elevate and create WOW moments within the context of an event. These experiences have been able to increase ROI of up to 140% for event customers under the NexTech brand portfolio.”

To learn more about NexTech AR, please visit www.nextechar.com.

About techsytalk 

techsytalk was founded by event planners with over a decade of experience planning meetings, conferences, and other corporate events in both live and virtual settings. techsytalk LIVE Global promises to be a resource to facilitate the evolution of the events and meeting industry in an increasingly tech-centric world.

About NexTech AR

NexTech is one of the leaders in the rapidly growing Augmented Reality market estimated to grow from USD $10.7B in 2019 and projected to reach USD $72.7B by 2024 according to Markets & Markets Research; it is expected to grow at a CAGR of 46.6% from 2019 to 2024.

The company is pursuing four verticals: 


InfernoAR:
 An advanced Augmented Reality and Video Learning Experience Platform for Events, is a SaaS video platform that integrates Interactive Video, Artificial Intelligence and Augmented Reality in one secure platform to allow enterprises the ability to create the world’s most engaging virtual event management and learning experiences. Automated closed captions and translations to over 64 languages. According to Grandview Research the global virtual events market in 2020 is $90B and expected to reach more than $400B by 2027, growing at a 23% CAGR. With NexTech’s InfernoAR platform having augmented reality, AI, end-to-end encryption and built in language translation for 64 languages, the company is well positioned to rapidly take market share as the growth accelerates globally.


ARitize™ For eCommerce:
 The company launched its SaaS platform for webAR in eCommerce early in 2019. NexTech has a ​‘full funnel’ end-to-end eCommerce solution for the AR industry including its Aritize360 app for 3D product capture, 3D/AR ads, its ARitize white label app it’s ‘Try it On’ technology for online apparel, 3D and 360-degree product views, and ‘one click buy’.


ARitize™ 3D/AR Advertising Platform:
 Launched in Q1 2020 the ad platform will be the industry’s first end-to-end solution whereby the company will leverage its 3D asset creation into 3D/AR ads. In 2019, according to IDC, global advertising spend will be about $725 billion.


ARitize™ Hollywood Studios
: The studio is in development producing immersive content using 360 video, and augmented reality as the primary display platform.

To learn more, please follow us on TwitterYouTubeInstagramLinkedIn, and Facebook, or visit our website: https://www.nextechar.com.

On behalf of the Board of NexTech AR Solutions Corp.

Evan Gappelberg” CEO and Director

For further information, please contact:

Evan Gappelberg
Chief Executive Officer
[email protected]   

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. 



MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte

ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) —  

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that $25 million in milestones have been achieved under its exclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA0012). The milestones were triggered by clinical and regulatory activities related to the further advancement of the molecule, including the recent initiation of POD1UM-303, Incyte’s Phase 3 global study in patients with metastatic squamous cell anal carcinoma (SCAC).

MacroGenics and Incyte have each established multiple development programs for retifanlimab, evaluating the anti-PD-1 molecule either as monotherapy or in combination with other agents. Incyte is conducting clinical trials that are potentially registration-enabling for patients with metastatic non-small cell lung cancer, SCAC, microsatellite instability high endometrial cancer and Merkel cell carcinoma. MacroGenics is conducting a potentially registration-enabling study of retifanlimab in combination with margetuximab, an investigational Fc-engineered, anti-HER2 mAb, in HER2-positive gastric cancer.

“We are excited to see the continued advancement of the development of retifanlimab across a broad set of monotherapy and combination regimens,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We look forward to continued progress on this program over the coming months.”

Under the collaboration agreement with Incyte, MacroGenics is eligible to receive up to a total of $365 million in potential remaining development and regulatory milestones and up to $330 million in potential commercial milestones. If retifanlimab is approved and commercialized, MacroGenics would be eligible to receive royalties, tiered from 15 to 24 percent, on future worldwide net sales of the molecule.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “subject to”, “believe”, “anticipate”, “plan”, “expect”, “intend”, “estimate”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company’s product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19), and other risks described in the Company’s filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

###



Contacts:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, [email protected]

People Corporation Deepens its Canadian Presence with the Acquisition of Three Benefits Firms in Each of Quebec, B.C. and Alberta


  • Alliance Pour La Santé Etudiante Au Quebec Inc. significantly


    expands


    People Corporation’s position in the post-secondary student benefits consulting


    and administration


    market.


  • ENCOMPASS


    Benefits & HR Solutions Inc. adds to the Company’s group benefits and group retirement consulting operations in B.C.


    ,


    enhancing


    People Corporation’s national capabilities.

  • Watermark Benefit Consulting Inc.


    designs


    and


    delivers


    group benefits and group retirement solutions


    ,


    with deep expertise serving


    organizations with international employee bases.

WINNIPEG, Manitoba, Nov. 30, 2020 (GLOBE NEWSWIRE) — People Corporation (the “Company”) (TSX Venture: PEO) announced today that it has entered into a definitive agreement to acquire Alliance Pour La Santé Etudiante Au Quebec Inc. (“ASEQ”), and has also recently closed the acquisitions of Watermark Benefit Consulting Inc. (“Watermark”) and ENCOMPASS Benefits & HR Solutions Inc. (“ENCOMPASS”).

Acquisition of
Alliance Pour La Santé Etudiante Au Quebec Inc.

The Company has entered into a definitive agreement to acquire ASEQ, a privately-owned benefits consulting and administration firm focused on post-secondary students (the “Transaction”). Established in 1996, ASEQ currently serves approximately 650,000 students through approximately 100 student associations and post-secondary institutions in six Canadian provinces. The addition of ASEQ to the People Corporation group of companies establishes the Company as a market leader in the segment, expanding its current capabilities and enhancing the Company’s ability to deliver market leading benefit solutions to post-secondary students. ASEQ’s founder and management team will continue to run the operations as part of People Corporation, and ASEQ’s highly talented team of approximately 150 consultants and staff will continue to provide innovative solutions to students.

Laurie Goldberg, Executive Chairman and CEO of People Corporation, commented, “We are very excited to announce the acquisition of ASEQ, which is a leader in the highly attractive student benefits sector. ASEQ is a perfect complement to our existing Gallivan and ACL student-focused operations, establishing People Corporation as a top national provider of student benefits solutions. By adding ASEQ to our platform, we have also broadened our suite of proprietary products and services, enhanced our national scale and capabilities, and meaningfully grown our market position in Quebec. We are thrilled to welcome the highly talented ASEQ team into the People Corporation family.”

People Corporation has agreed to acquire 100% of the issued and outstanding shares of ASEQ from a group of shareholders for a purchase price of $56.4 million, subject to post-closing adjustments. Of the total purchase price, $50.0 million will be paid in cash on closing of the Transaction, and the remaining $6.4 million will be paid by way of deferred payments following the second anniversary of the closing, subject to potential adjustment related to the financial performance of the business. In addition, ASEQ shareholders may be eligible to receive additional payments in the four years following closing of the Transaction should the business exceed certain financial performance thresholds. The Closing of the ASEQ Transaction, which is subject to customary conditions, is expected to occur in early December.

Acquisition of
ENCOMPASS
Benefits & HR Solutions Inc.

Based in Kelowna, British Columbia, ENCOMPASS takes a holistic approach to providing its clients a full suite of group benefits, group retirement, HR services and health and wellness solutions. ENCOMPASS’ principal, Bret Loge, will continue to operate the business as part of People Corporation, and his talented team will continue to provide extraordinary service and advice to the company’s clients. The addition of ENCOMPASS will enhance People Corporation’s national capabilities while continuing to grow its presence in British Columbia, particularly in the interior region of the province.

Mr. Goldberg commented, “ENCOMPASS has built a robust business based on a foundation of stable, long-term client relationships and exceptional service. The addition of ENCOMPASS to our national platform will both enhance People Corporation’s national capabilities and further grow our presence in the Province of British Columbia. We are very excited to welcome Bret and his team to the People Corporation group of companies.”

Acquisition
of
Watermark Benefit Consulting Inc.

Founded in 1993 and based in Calgary, Alberta, Watermark specializes in providing employee benefits and group retirement solutions to companies with international and domestic operations. Watermark has developed a highly-trusted brand by providing superior value to its clients in addressing their varying needs for their global workforces through sophisticated advice on plan design, client service and access to a broad product portfolio. Watermark’s founder and principal, Jean Iozzo, will continue to run the operations as part of the People Corporation group of companies.

“People Corporation’s offering to enterprise-sized clients continues to expand, along with the demand for advice and solutions focused on organizations with international workforces,” said Mr. Goldberg. “Watermark has established itself as one of Canada’s top specialists in this area, and their deep expertise in international benefits will be additive to our enterprise capabilities. We have known the Watermark team for many years and I am pleased to welcome them as part of the People Corporation family.”

Exercise of Accordion Option on Credit Facility

The Company also announced today that, in conjunction with these acquisitions, it has exercised the accordion option on its senior credit facility (the “Facility”) to increase the size of the Facility by $50 million, to a total of $175 million overall.


About People Corporation

People is a leading independent national provider of group benefits, group retirement and human resource solutions. With over 1,100 talented employees operating through 40 offices across Canada, we serve organizations from coast to coast, enabled by proprietary technology platforms and solutions. Our industry and subject matter experts deliver uniquely valuable insights while customizing our innovative suite of services to the specific needs of each client. Whatever your sector, whatever your scale, putting our expertise and proven track record to work will make a difference to your people and your bottom line.

For more information, please visit www.peoplecorporation.com.


Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable securities laws, such as statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Use of words such as “may”, “will”, “expect”, “believe”, “intends”, “likely”, or other words of similar effect may indicate a “forward-looking” statement. These statements are not guarantees of future performance and are subject to numerous risks and uncertainties, including those described in the Company’s publicly filed documents (available on SEDAR at www.sedar.com). Those risks and uncertainties include the ability to maintain profitability and manage organic or acquisition growth, reliance on information systems and technology, reputation risk, dependence on key clients, reliance on key professionals and general economic conditions. Many of these risks and uncertainties can affect the Company’s actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statement made by the Company or on its behalf. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. All forward-looking statements in this news release are qualified by these cautionary statements. These statements are made as of the date of this news release and, except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, its financial or operating results or its securities.


Investor Relations Inquiries:

Jonathan Ross, CFA
Investor Relations – People Corporation
(416) 283-0178
[email protected]

Dennis Stewner, CPA, CA
CFO and COO – People Corporation
(204) 940-3988
[email protected] 
www.peoplecorporation.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.



REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event

Online
Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

CELEBRATION, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, will co-host an online investor event with Corium, Inc. to discuss the potential commercialization strategy for KP415 and the anticipated opportunity for the drug product as a potential new entry into the attention deficit hyperactivity disorder (ADHD) marketplace if approved by the U.S. Food and Drug Administration (FDA). The online event will be held on Wednesday, December 2, 2020, beginning at 10:00 a.m., ET, and can be accessed via KemPharm’s Investor Relations website (http://investors.kempharm.com/) and the following URL: https://edge.media-server.com/mmc/p/wpaovm9r

Event:   KP415 Market Opportunity and Commercialization Strategy
Date:    Wednesday, December 2, 2020
Time:    10:00 AM (ET)
Live Webcast
:
  https://edge.media-server.com/mmc/p/wpaovm9r
Format:   Audio webcast with slide presentation

Interested participants and investors may also access the event by dialing:

  • (866) 395-2480 (U.S.)
  • (678) 509-7538 (international)
  • Conference ID: 9652705 

An archive of the webcast and presentation will be available via the Investor Relations section of the Company’s website, http://investors.kempharm.com/, for 90 days beginning at approximately 12:30 p.m. ET, on December 2, 2020.

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LATTM technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of ADHD and stimulant use disorder. KemPharm’s co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential FDA approval of KP415, the potential commercial launch of KP415, the anticipated market for KP415 if it were to be approved by the FDA, the potential clinical benefits of KP415 or any of the Company’s product candidates, are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm’s business are described in detail in KemPharm’s Annual Report on Form 10-K for the year ended December 31, 2019, KemPharm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

KemPharm Contacts:
Jason Rando / Maureen McEnroe
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
[email protected]
[email protected]

 



Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs


  • FDA’s review confirms


    use of Negative Binomial


    m


    odel for


    analysis


    of primary endpoint in


    ongoing


    OTIVIDEX


    Phase 3 trial in


    Ménière’s


    disease


    ; results still expected in first quarter of 2021


  • Company finalizing d


    esign of Phase 2


    trial


    for


    OTO-313 in tinnitus


    and expects to start study in the first quarter of 2021

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided updates regarding the statistical analysis plan for the ongoing Phase 3 trial of OTIVIDEX in Ménière’s disease, and outlined plans for a Phase 2 trial of OTO-313 in tinnitus.

  • OTIVIDEX
    : FDA
    ’s review
    of the OTIVIDEX statistical analysis plan
    confirms
    use of the Negative Binomial model for analysis of the primary endpoint in the ongoing
    Phase 3 clinical t
    rial
    in
    Ménière’s
    d
    isease
    . In July 2020, Otonomy submitted a revised statistical analysis plan for the ongoing trial to the U.S. Food and Drug Administration (FDA) that proposed use of the Negative Binomial model for primary analysis of the daily vertigo count data reported by patients. Otonomy believes that this statistical test provides the best fit of the OTIVIDEX clinical data based on the Phase 2b trial, the AVERTS-2 Phase 3 trial, and the integrated dataset from both trials. As previously reported, the ongoing Phase 3 clinical trial has completed enrollment and results are expected in the first quarter of 2021. Assuming positive results, submission of a New Drug Application to the FDA is planned for the third quarter of 2021.

  • OTO-313
    :
    Phase 2 trial
    design
    to be
    based on
    the successful
    Phase 1/2
    trial
    ,
    and
    initiation is expected
    in the first quarter of 2021
    . In July 2020, Otonomy reported positive top-line results from a Phase 1/2 trial of OTO-313 in patients with unilateral tinnitus of at least moderate severity. This trial demonstrated a positive clinical response for a single intratympanic injection of OTO-313 using the Tinnitus Functional Index (TFI) that was correlated with tinnitus loudness, tinnitus annoyance and patient global impression of change measures. Based on continued analysis of this data, input from key opinion leaders, and feedback from the FDA in a Type C meeting, Otonomy intends to evaluate the same dose for OTO-313 in a Phase 2 trial that will enroll an enriched unilateral tinnitus patient population. To enrich the study population, Otonomy intends to exclude patients with severe hearing loss and increase the minimum TFI score required for entry. The company will also expand the unilateral patient population eligible for enrollment by increasing the time from tinnitus onset, and will extend the observation period to assess durability of the treatment effect.

“We appreciate the timely feedback from the FDA that supports our plan to analyze the OTIVIDEX Phase 3 trial results and, together with input from tinnitus clinical experts, will help us finalize the OTO-313 Phase 2 trial design,” said David A. Weber, Ph.D., president and CEO of Otonomy. “We are looking forward to having the OTIVIDEX results and initiating the OTO-313 Phase 2 trial in the first quarter of 2021. In the meantime, we are working to complete the OTO-413 Phase 1/2 trial in patients with speech-in-noise hearing deficit, and expect to announce results in December.”

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the future financial or operating performance of Otonomy. Forward-looking statements in this press release include, but are not limited to, statements relating to the design of (including without limitation regarding dose and patient population), initiation of, development activity for, and advancement of clinical trials; statements relating to the timing of results, activity for, and conduct of ongoing clinical trials; statements relating to the updated statistical analysis plan for the ongoing Phase 3 clinical trial of OTIVIDEX and expectations regarding the Negative Binomial model; statements regarding plans to submit a New Drug Application for OTIVIDEX; and statements by Otonomy’s president and CEO. Otonomy’s expectations regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties. Actual results may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: delays and disruption resulting from the COVID-19 pandemic and governmental responses to the pandemic, including current and future impacts to Otonomy’s operations, the manufacturing of its product candidates, the progression of its current clinical trials, enrollment in its current and future clinical trials and patient conduct and compliance; Otonomy’s ability to accurately forecast financial results; Otonomy’s ability to obtain additional financing; Otonomy’s dependence on the regulatory success and advancement of its product candidates; the uncertainties inherent in the clinical drug development process, including, without limitation, Otonomy’s ability to adequately demonstrate the safety and efficacy of its product candidates, the nonclinical and clinical results for its product candidates, which may not support further development, and challenges related to patient enrollment in clinical trials; the integrity of patient-reported outcomes in its current and future clinical trials; the risks of the occurrence of any event, change or other circumstance that could impact Otonomy’s ability to repay or comply with the terms of the loan provided by Oxford Finance LLC; side effects or adverse events associated with Otonomy’s product candidates; Otonomy’s ability to successfully commercialize its product candidates, if approved; competition in the biopharmaceutical industry; Otonomy’s dependence on third parties to conduct nonclinical studies and clinical trials, and for the manufacture of its product candidates; Otonomy’s ability to protect its intellectual property in the United States and throughout the world; Otonomy’s ability to manage operating expenses; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Otonomy’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 4, 2020, and Otonomy’s future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof. Otonomy disclaims any obligation to update any forward-looking statements, except as required by law.

Contacts:

Media Inquiries
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
[email protected]

Investor Inquiries
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
[email protected]



Ebix and Data Glove Technologies Sign Strategic Outsourcing and Joint Venture Agreement to Offer Cloud and Infrastructure Support Services to the Insurance, Banking and Healthcare Industries

JOHNS CREEK, Ga., Nov. 30, 2020 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries today announced a strategic agreement with Data Glove Technologies, a New Jersey based firm specializing in Infrastructure, Managed Services and Cloud Services. The agreement entails various facets including outsourcing of certain back office functions and strategic joint ventures (JV) to provide cloud and infrastructure support services to the Insurance, Banking and Healthcare marketplace.

The Companies announced the setting up of two joint ventures in the US and India to target the cloud and infrastructure support areas in the BFSI industry in both geographies. The JV in the US will target the US and Candian markets while another JV set up in India will service the Asia Pacific, Africa, Europe and ASEAN Regions. The joint ventures will focus on providing Infrastrucuture Assessment including Cloud Readiness, Cloud Migration, Development Services (Dev Ops), and Maintenance Services for both Public and Private Cloud solutions.

Robin Raina, Chairman, CEO, and President of Ebix said, “The combination of Ebix and Data Glove in the field of cloud computing and infrastructure support is compelling. Data Glove’s deep and proven expertise in the Cloud space, combined with Ebix’s footprint of software products in the insurance and financial industries provides us with a unique combination that none of the other cloud and infrastructure support companies have. This initiative aligns well with our desire to continue to invest in our core insurance businesses in North America. I expect $10+million of revenues, from this arrangement in 2021.”

Rahul Bajaj, EVP, Global Revenue & New Growth Initiatives, Data Glove said “We are very excited about this win-win partnership with Ebix. Data Glove has been growing organically at 30%+levels annually. In Ebix, we found a Company who has made deep inroads in the insurance and financial industries, while powering billions of dollars of domain rich on-demand transactions annually.”

Rajiv Korpal, EVP, Global Sales and Services, Data Glove said “This JV will have a simple goal: to provide transformative solutions that deliver exceptional outcomes. The combined blend of industry domain expertise and cloud & infrastructure support expertise positions us together as a powerful force, to win large strategic deals in these industries.”

Ash Sawhney, President, Insurance Solutions North America said, “This is a significant addition to our repertoire of offerings in North America, and a very timely one. Establishing a Cloud strategy and developing a roadmap is a key priority for most of our clients, which include hundreds of top tier insurance companies, healthcare companies, banks, and large distributors. The insurance and financial industries continue to be supported by legacy backoffice systems which are hard and expensive to maintain. Our goal is to create a roadmap to migrate those legacy applications to the Cloud thereby bringing enormous efficiencies and cost savings to our customers.”

About Ebix, Inc.

With 50+ offices across 6 continents, Ebix, Inc., (NASDAQ: EBIX) endeavors to provide On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries. In the Insurance sector, Ebix’s main focus is to develop and deploy a wide variety of insurance and reinsurance exchanges on an on-demand basis, while also providing Software-as-a-Service (“SaaS”) enterprise solutions globally in the area of CRM, front-end & back-end systems, outsourced administration and risk compliance services.

With a “Phygital” strategy that combines 320,000 physical distribution outlets in many Southeast Asian Nations (“ASEAN”) countries, to an Omni-channel online digital platform, the Company’s EbixCash Financial exchange portfolio encompasses leadership in the areas of domestic & international money remittance, foreign exchange (Forex), travel, pre-paid & gift cards, utility payments, and lending, wealth and asset management solutions and services in India and other markets. EbixCash’s Forex operations have emerged as a leader in India’s airport Foreign Exchange business, with operations in 32 international airports, including Delhi, Mumbai, Bangalore, Hyderabad, Chennai and Kolkata. These Forex operations conduct over $4.8 billion in gross transaction value per year. EbixCash’s inward remittance business in India conducts approximately $5 billion gross in annual remittance business, confirming its undisputed leadership position in India. EbixCash, through its travel portfolio of Via and Mercury, is also one of Southeast Asia’s leading travel exchanges, with over 2,200+ employees, a 212,450+ agent network, 25 branches and over 9,800 corporate clients. The EbixCash travel business processes an estimated $2.5 billion in gross merchandise value per year. EbixCash’s technology services Division has emerged as a leader in the areas of lending technology, asset & wealth management technology, and travel technology in India and has grown its international expanse to Europe, Middle East, Africa and other ASEAN countries.

Through its various SaaS-based software platforms, Ebix employs thousands of domain-specific technology professionals to provide products, support and consultancy to thousands of customers on six continents. For more information, visit the Company’s website at www.ebix.com

About Data Glove Inc.

With a staff of 600+ employees across 9 international locations, Data Glove is a leading, fast growing global provider of Business Transformation Services with a focus across four core services: Digital Transformation, Workplace Transformation, Application Transformation and Intelligent Automation. The Company’s focus is on delivering industry-specific services across banking, financial services & insurance, retail, public sector hospitality and telecom to support growth and continuous digital transformation journeys.

Data Glove empowers BFSI clients to grow revenue, improve customer engagement, manage risk and streamline processes for efficiency, while remaining competitive and innovative. For more information, visit the Company’s website at www.dataglove.com

CONTACT:

Darren Joseph
678-281-2027 or [email protected]

David Collins or Chris Eddy
Catalyst Global – 212-924-9800 or [email protected] 



Interim Results for the Period Ended September 30, 2020

Good performance from projects and operations

Iain Ross, CEO, Golar LNG, said:

“Golar is pleased to report Q3 operating revenues of $95.2 million and adjusted EBITDA1 of $57.3 million, driven by a tenth consecutive quarter of uninterrupted commercial uptime in FLNG. Q3 TCE1 for the fleet at $39,100/day is above prior guidance of $35,000/day and driven by a higher year on year utilization of 80% for the quarter. TCE1 from the TFDE1 vessels excluding dry-dock days amounted to $43,800 for the quarter.

We concluded the force majeure event with BP on the Gimi FLNG project, which resulted in an anticipated delay of 11 months to the project. All other terms of the 20 year lease and operating agreement remained unchanged. The project has ramped up manning levels to pre-lockdown numbers and remains on track to the new dates and with no material change to the overall project budget.

The Viking conversion project is on track for completion and customer acceptance before the end of the year with the now re-named vessel LNG Croatia currently preparing for commissioning activities.  Upon acceptance by LNG Hrvatska, expected in December, the project will release approximately $17 million of cash to Golar, with a further $30 million expected in January 2021.

The power station in Sergipe including FSRU Nanook earned full capacity payments during the quarter. Golar’s 50% proportionate share of Hygo Energy Transition Ltd’s adjusted EBITDA1 for the quarter, amounted to $15.6 million.”

Financial Summary

(in thousands of $) Q3 2020 Q3 2019 % Change YTD 2020 YTD 2019 % Change
             
Total operating revenues 95,152 98,670 (4)% 319,953 309,702 3%
Net loss attributable to Golar LNG Ltd (21,802) (82,301) (74)% (281,683) (236,724) 19%
Adjusted EBITDA1 57,287 58,932 (3)% 200,645 161,492 24%
Operating income 30,632 (13,666) (324)% 80,148 (8,237) (1073)%
Dividend per share —% 0.150 (100)%
Adjusted net debt1 2,649,778 2,294,932 15% 2,649,778 2,294,932 15%

Q3 highlights and recent events

Financial:

  • Received committed terms for a new $100 million credit facility backed by Golar’s interest in Hygo Energy Transition Ltd. (“Hygo”).
  • Term sheet in advanced discussion with a major bank for an incremental $125 million credit facility, drawable upon IPO of Hygo.
  • A further $75 million drawn down against FLNG Gimi debt facility concluded in Q4.
  • Additional proposals that would improve liquidity by around $70 million currently under consideration. These include a refinancing of Golar Frost for which terms have been received and an extension or refinancing of the margin loan secured by our interest in Golar LNG Partners LP (“Golar Partners”). The financing of Golar Seal has been extended to January 2022.
  • Callum Mitchell-Thomson who joined in April has, for personal reasons, decided to resign from his position as CFO. The Board wants to thank Callum for his valuable contribution during the time he was here. His function will now be assumed by Karl Fredrik Staubo, who, for the time being, will also remain as CEO of Golar Partners.

Shipping:

  • Shipping results adversely impacted by Golar Tundra’s extended dry-dock due to Singapore lockdown preventing any work for several months.
  • Q3 2020 average daily Time Charter Equivalent (“TCE”)1 earnings of $39,100 for the fleet, above guidance and higher than the $35,200 achieved in Q3 2019.
  • Utilization at 80%, down on the 93% achieved in Q2 2020 but up on the 65% realized in Q3 2019 as a result of a stronger contract portfolio.
  • Q3 2020 TFDE1 vessel TCE1 of $43,800, excluding days in dry dock.
  • Conclusion of several term contracts added $123 million of revenue backlog1 during Q3 to date resulting in $198 million of revenue backlog1 as at 30 September.
  • Downside risk materially reduced through increased utilization and fixed rate charter coverage.

FLNG:

  • FLNG Hilli Episeyo off-loaded 47th cargo, with 100% commercial uptime maintained. Scheduled maintenance shutdown completed in October without issue.
  • Agreed revised FLNG Gimi project schedule with BP, ending the force majeure event under the Lease and Operate Agreement (“LOA”) with BP.
  • Agreed amendment to FLNG Hilli Episeyo tolling agreement that removes cap on gas reserves available for future liquefaction and allows for billing of prior and future over production.
  • Constructive discussions on proving up additional reserves and increasing utilization of Hilli Episeyo ongoing with charterers.
  • Continued to develop pipeline of future FLNG opportunities with strong counterparties. Five incremental FLNG opportunities added to the four existing opportunities that continue to be developed.
  • Entered into a collaboration agreement with Black & Veatch Corporation (“B&V”) to research and, if appropriate, develop, solutions for the floating production of blue and green ammonia as well as carbon reduction in LNG production.

Hygo Energy Transition Ltd:

  • Paul Hanrahan, former CEO of AES Corporation, appointed as CEO of Hygo.
  • Received Installation License for the construction of the Barcarena power station and associated LNG Terminal.
  • Awarded port concession for the long-term use of existing facilities in the Vila do Conde Port located in Barcarena.
  • Signed MoU with Pará state distribution company for use of the Barcarena terminal to supply regional demand for cleaner fuels, replacing MoU with Norsk Hydro.
  • Extensive forensic review of Hygo business conduct initiated by the Hygo Board. The work conducted by external experts has confirmed no issues of concern and robust corporate governance and compliance policies.

Outlook

LNG Shipping:

We expect the Q4 2020 fleet TCE1 to be above $50,000 per day, with utilization above 80% based on fixtures to date and prevailing spot market conditions. Our shipping strategy continues to prioritize longer term utilization over short-term opportunities, but we remain adequately exposed to seasonal and other potential upside by virtue of some index linked charters within the portfolio. Golar has fixed around two thirds of available 2021 revenue days through a combination of fixed and floating rate charters. Following Golar Tundra’s departure from the shipyard in October, no further dry-docks are scheduled for the fleet until 2023. 

FLNG:

We will continue to focus on Gimi productivity and to manage re-schedule progress and safe working under COVID-19 restrictions. The project’s 4th dry dock is scheduled to commence in early December 2020.

The scheduled maintenance shutdown in October will not result in any reduction in Q4 FLNG earnings from Hilli Episeyo. We continue to work with our counterparts Perenco and SNH on potential solutions to increase throughput on the vessel. Subject to final signature from SNH, expected shortly, removal of the cap on feed gas available for liquefaction in Cameroon is an important step that will facilitate this. Additional revenue amounting to $5.1 million covering overproduction by the vessel in 2019 will be invoiced shortly after signature. Golar’s strong operating track record has created a good relationship with our charterer which is facilitating constructive discussions with the target to prove up more reserves and increase utilization of the vessel. Should these discussions be concluded successfully, there will likely be a new risk aligned tariff payment for the additional volumes.

Golar will continue to develop its portfolio of FLNG opportunities featuring both its 3.5 and 5mtpa Mark III new build FLNG vessel designs as direct competitors to traditional large-scale onshore liquefaction facilities, in addition to marketing the proven Mark I solution. The project portfolio has grown considerably over the last few months and it is interesting to observe an increasing number of requests from oil majors seeking lower cost production solutions. Whilst it is difficult to see a Final Investment Decision (“FID”) in 2021, this volume of enquiries creates confidence in the competitiveness of our FLNG products and the long-term future of this business. The lack of FIDs in the LNG business in recent years combined with strong demand will result in higher LNG prices that will likely generate additional interest in Golar’s FLNG solutions.

Following the recent signing of the collaboration agreement with B&V, we will jointly work on solutions to further reduce the (already competitive) carbon footprint of our FLNGs and for the potential development of floating ammonia production.

Hygo Energy Transition Ltd:

The Hygo Board will consider the timing for a potential re-launch of the IPO which will be driven by market conditions,  ongoing business operations and ongoing business development activity.

Hygo expects to take a FID on the Barcarena terminal before the end of the year based on the expressed interest for off-take volumes from industrial users. FID on the associated 605MW power station is expected to follow approximately 6-months after FID of the terminal.

Additionally, Hygo remains actively involved in the development of several other terminal opportunities in Brazil on a competitive basis, including terminals in Suape and Bahia. Further clarifications with regards to the final outcome of those processes are expected in the coming months. 

Corporate:

Although postponed by recent events, Golar remains committed to the separation of Hygo and an IPO remains the primary route to achieve this, subject to approval of the Hygo board, ongoing business operations and business development activity. When concluded, the separation will represent the first step toward re-organizing and simplifying Golar’s structure.

Based on results achieved to date, Q4 adjusted EBITDA1 should show a solid improvement versus Q3. Golar group contract earnings backlog1 currently stands at $10.3 billion, of which Golar LNG Limited’s pro-rata share amounts to $6.0 billion. The Board is pleased by the way the company has strategically positioned itself in this high growth market. Supported by the contract earnings backlog1 above, we anticipate further strong growth in adjusted EBITDA1. This together with a simplification of the corporate structure can unlock value and create a solid return to shareholders going forward. 

Financial Review

Business Performance:

  2020
  Jul-Sep Apr-Jun
(in thousands of $) Vessel and other operations FLNG Total Vessel and other operations FLNG Total
Total operating revenues 40,628    54,524    95,152    47,718    54,524    102,242   
Vessel operating expenses (14,951)   (13,282)   (28,233)   (11,336)   (12,907)   (24,243)  
Voyage, charterhire & commission expenses (including expenses from collaborative arrangement) (476)   —    (476)   (1,539)   —    (1,539)  
Administrative expenses (7,816)   (173)   (7,989)   (8,348)   (246)   (8,594)  
Project development expenses (1,136)   (31)   (1,167)   (982)   (266)   (1,248)  
Other operating gains —    —    —    532    —    532   
Adjusted EBITDA(1) 16,249    41,038    57,287    26,045    41,105    67,150   
             
Reconciliation to operating income            
Unrealized gain (loss) on oil derivative instrument(2) —    220    220    —    (11,810)   (11,810)  
Depreciation and amortization (14,890)   (11,985)   (26,875)   (14,997)   (11,985)   (26,982)  
Operating income 1,359    29,273    30,632    11,048    17,310    28,358   

(2) The line item “Realized and unrealized gain / (loss) on oil derivative instrument” relating to income from the FLNG Hilli Episeyo Liquefaction Tolling Agreement is split into, “Realized gain on oil derivative instrument” and “Unrealized loss on oil derivative instrument”. The unrealized component represents a mark-to-market gain of $0.2 million (June 30, 2020: $11.8 million loss) on the oil embedded derivative, which represents the estimate of expected receipts under the remainder of the Brent oil linked clause of the Hilli Episeyo Liquefaction Tolling Agreement. The realized component amounts to $nil (June 30, 2020: $nil) and represents the income in relation to the Hilli Episeyo Liquefaction Tolling Agreement receivable in cash.

Golar reports today Q3 operating income of $30.6 million compared to operating income of $28.4 million in Q2.

Total operating revenues decreased 7% from $102.2 million in Q2 to $95.2 million in Q3, partially mitigated by a decrease in voyage, charter hire and commission expenses, from $1.5 million in Q2 to $0.5 million in Q3. A COVID-19 induced closure of the shipyard where Golar Tundra was being dry-docked resulted in significant unscheduled off hire during the quarter and contributed to the reduction in fleet utilization, from 93% in Q2 to 80% in Q3. Low LNG prices also contributed to a large number of cargo cancellations, predominantly out of the US, that suppressed both shipping demand and spot rates, and reduced the daily rate achieved in respect of Golar’s spot and index linked charters.

Revenue from vessel and other operations, including management fee income, net of voyage, charterhire and commission expenses, was $40.2 million and decreased by $6.0 million from $46.2 million in Q2. Further US cargo cancellations over summer, higher than normal European storage levels and weather related supply interruptions resulted in a slower than normal seasonal recovery in shipping rates. From early August, supply outages in Australia and demand recovery in Asia boosted spot LNG prices that subsequently supported inter-basin trading. Sufficient available tonnage to meet near term demand meant that increased chartering activity for US loadings did not result in a meaningful increase in charter rates until later in the month. Hurricane related interruptions again constrained US supply in September, temporarily halting further increases in carrier rates whilst further boosting LNG prices. As production resumed, a widening west-east arbitrage quickly absorbed available vessels and freight rates resumed their upward seasonal trajectory toward the end of the quarter. The quarter began with quoted TFDE1 carrier headline spot rates at around $30k/day and ended with rates at around $59k/day. Delays to the seasonal recovery and a prolonged dry-dock of the Golar Tundra, offset by improved coverage as a result of a utilization focused strategy meant that full fleet TCE1 earnings decreased from $45,100 in Q2 2020 to $39,100 in Q3 2020, but increased relative to the $35,200 achieved in Q3 2019.

Operating revenues from FLNG Hilli Episeyo remained stable at $54.5 million, including base tolling fees and amortization of pre-acceptance amounts recognized.

As expected, vessel operating expenses at $28.2 million were higher than those of Q2 at $24.2 million.
Of the $4.0 million increase, $2.5 million is due to a non-recurring insurance recovery received in Q2 with the remainder largely attributable to catch-up repairs and maintenance carried out following the lifting of COVID restrictions over the northern hemisphere summer months.

Administrative expenses decreased by 8% from $8.6 million in Q2 to $8.0 million in Q3. This was driven by ongoing cost reduction measures. Project development expenses at $1.2 million for the quarter were in line with Q2. Depreciation and amortization, at $26.9 million was also in line with the prior quarter.

Net Income Summary:

  2020
(in thousands of $) Jul-Sep Apr-Jun
Operating income 30,632    28,358   
Interest income 29    243   
Interest expense (16,093)   (17,003)  
Gains(losses) on derivative instruments (4,686)   4,864   
Other financial items, net 1,997    (337)  
Income taxes (216)   (185)  
Equity in net losses of affiliates (3,559)   (139,365)  
Net income attributable to non-controlling interests (29,906)   (32,209)  
Net loss attributable to Golar LNG Limited (21,802)   (155,634)  

In Q3, the group generated a $21.8 million net loss, compared to a Q2 net loss of $155.6 million. Key items contributing to this are:

  • A $4.7 million Q3 loss on derivative instruments due to a further decline in LIBOR rates in the quarter, and foreign exchange rate movements.
  • The $3.6 million loss in Q3 for equity in net losses of affiliates primarily comprises the following:
      • A $8.0 million net loss in respect of Golar’s 50% share in Hygo; and
      • A $4.6 million net gain in respect of Golar’s 32% share in Golar Partners. Q2 was negatively impacted by a $135.9 million impairment of our investment in the Partnership.

Net losses attributable to non-controlling interests relate to the Hilli Episeyo, the Gimi and the finance lease VIEs.

Financing and Liquidity:

Our cash position as at September 30, 2020 was $238.9 million. This was made up of $76.7 million of unrestricted cash and $162.2 million of restricted cash. Restricted cash includes $61.7 million relating to lessor-owned VIEs and $75.9 million relating to the Hilli Episeyo Letter of Credit, of which $15.2 million has been classified as short-term and is expected to be released to free cash in Q2 2021 when the next Hilli Episeyo production milestone is forecast to be met.

After repayment of the vessel debt facility, Golar expects to release a further $17 million of cash in December 2020 and $30 million in January 2021 following the sale of the converted FSRU LNG Croatia (formerly Golar Viking) to LNG Hrvatska.

Golar has received committed terms for a new $100 million credit facility secured by our shareholding in Hygo, to replace the current $150 million facility currently secured by our interest in Hygo. Golar is also in advanced discussions on a term sheet with a major bank for an additional $125 million credit facility, drawable upon the IPO of Hygo.

At the vessel level, the current providers of the Golar Seal facility have extended the financing to January 2022. The company has also received two financing proposals from financial institutions for an opportunistic refinancing of the Golar Frost. The proposed terms could potentially release up to $40 million of liquidity in Q1 2021, subject to approval and final documentation.

At the FLNG level, a gradual re-opening of Keppel Shipyard following the Singapore “circuit breaker” continued to limit construction progress during the quarter with milestones and payments impacted accordingly. Inclusive of $7.4 million of capitalized interest, $45.7 million was invested in FLNG Gimi during the quarter, taking the total invested as at September 30 to $598.7 million. Of this, $225.0 million had been drawn against the $700 million debt facility. Both the investment and debt drawn to date are shown on a 100% basis. Progress at the yard has since accelerated and there are now in excess of 2,400 yard workers allocated to the project. Following the step up in construction activity, Golar has drawn down a further $75 million against this facility in Q4 to date.

Included within the $1,215.4 million current portion of long-term debt and short-term debt as at September 30 is $1,017.8 million relating to lessor-owned VIE subsidiaries that Golar is required to consolidate in connection with ten sale and leaseback financed vessels, including the Hilli Episeyo

Corporate and Other Matters:

As at September 30, 2020, there were 97.8 million shares outstanding. There were also 2.2 million outstanding stock options with an average price of $28.87 and 1.0 million unvested restricted stock units awarded.

Golar’s Annual General Meeting was held on September 24, 2020.

On September 24, 2020, a single purported Golar shareholder filed a putative class action lawsuit against us, our CEO and the former CEO of Hygo. The complaint generally alleges a violation of the Securities Exchange Act of 1934, as amended, through the use of false and/or misleading statements regarding, among other matters, Golar’s business operations and prospects in relation to the implication of Hygo’s former chief executive officer in certain allegations by the Brazilian government. The complaint seeks unspecified damages, attorneys’ fees and other costs. We believe that the allegations in the lawsuit are without merit and intend to vigorously contest the class action lawsuit.

Commercial Review

LNG Shipping:

The quarter commenced with JKM at around $2.15/mmbtu and quoted TFDE headline spot rates of around $30k/day. Further US cargo cancellations over the summer months and higher than normal European storage levels resulted in a slower seasonal recovery in shipping rates. Hurricane related interruptions also cut US supply in early September and contributed to a buildup of tonnage in the Atlantic. This temporarily halted carrier rate increases being seen from late August and further boosted LNG prices that were increasing as a result of earlier supply re-balancing. As production resumed, a widening of the west-east arbitrage quickly absorbed available vessels and freight rates resumed their upward seasonal trajectory. The quarter ended with JKM at around $5.15/mmbtu and quoted TFDE headline spot rates of around $59k/day.

Full utilization of available US export capacity and increasingly long haul trades are currently supported by strong winter demand in key Asian markets and further supply outages elsewhere, leading to higher LNG prices and widening regional price differentials into Q4. By late October there were limited prompt available vessels and TFDE spot rates for some voyages exceeded $100,000 per day. Golar has taken advantage of the opportunity to fix some of its available vessels on term charters. Based on fixtures to date and accounting for remaining off-hire in respect of the now completed Golar Tundra dry-dock and some unscheduled maintenance of another carrier, Golar currently expects Q4 fleet utilization in excess of 80% and a TCE1 of above $50,000 per day. Revenue backlog1 from shipping fixtures to date amounts to $198 million as at September 30, with around two thirds of available 2021 trading days now covered.

Up to 20-25 million tons of un-utilized liquefaction capacity may return to the market in 2021. Growing underlying demand and limited new nameplate capacity additions through to 2023 are expected to result in comparatively high LNG prices and a forecast 13% growth in 2021 ton-mile demand for shipping. This will help absorb the 49 vessels expected to deliver in 2021. From 2024, projects with a combined nameplate capacity of around 100mtpa are then scheduled to start-up in phases. Deferral of 2020 scheduled FID decisions for new liquefaction capacity, particularly in North America, continues to discourage new build orders. Of the limited number of vessels ordered in 2020 to date, most are from oil majors seeking to upgrade their fleets.

FLNG:

Golar is pleased to have resolved the FLNG Gimi force majeure event under the LOA with BP. A new construction schedule that includes revised milestone payment dates has also been agreed with the yard. The 11-month delay to the start date is expected to result in a $36 million increase in the conversion budget, up from $1.330 billion to $1.366 billion. All other conditions of the 20-year Lease and Operate Agreement remain unchanged.

FLNG Hilli Episeyo, which completed its 2-week scheduled maintenance shutdown in October, continues to maintain 100% commercial uptime. It recently offloaded its 47th cargo and continues to reliably deliver quarterly LNG tolling revenues, less operating costs, of around $40 million; 50% of which is for GLNG’s account. Agreement has been reached with all parties to remove the 500bcf cap on feed gas available for liquefaction by Hilli Episeyo. Final signature from SNH is expected shortly. This is a key step toward a potential increase in utilization. Under the agreement, Perenco will pay for excess LNG produced to date. This equates to $5.1 million in additional revenue from COD through to the end of 2019, and any overproduction will continue to be billed going forward in Q1 each year.

Between July 2020 and the present date the number of potential new projects being actively discussed with charterers has materially increased. In most cases it is the potential counterparty who has approached Golar. The nine opportunities currently being discussed with financially strong counterparties are geographically spread and include potential deployments in West Africa, Asia, the Mediterranean and the Americas.

On November 18, 2020, Golar and B&V agreed to expand on their long-standing FLNG relationship and enter into a collaboration agreement in the field of floating ammonia production, carbon capture, and green LNG. Golar brings to the relationship its deep experience of delivering and operating paradigm shifting low cost floating LNG infrastructure that works, and B&V, as a leading provider of LNG technology also bring a deep expertise in green technologies. Within 2021, Golar and B&V will initially focus on floating ammonia production with carbon capture and storage (“Floating Blue Ammonia”) and will seek to establish the technical feasibility and commerciality of this methodology of developing hydrogen as a fuel. Any project development and implementation that follows the initial research and investigation stages above will be subject to a separate commercial agreement between the two companies.

Hygo Energy Transition Ltd (50/50 Golar/Stonepeak Infrastructure Partners non-consolidated downstream JV):

Although delayed by unforeseen events on September 24, Golar believes an IPO represents the best means of capturing the value of its downstream investment, depending on market conditions, ongoing business operations and ongoing business development activity. The allegations made against Hygo’s former CEO Eduardo Antonello pre-date and do not, in any way, implicate his work at Hygo or indeed any other Golar group company. Conscious both of his need to address the allegations and of the escalating harm to the business by association, Mr. Antonello stepped away from his role as Hygo CEO on September 29 and was replaced by Paul Hanrahan on October 19. Mr. Hanrahan brings to Hygo extensive international experience from substantial power producing businesses, including more than 10 years as CEO of AES Corporation. 

In response to the allegations, Hygo’s board initiated an internal review on September 25. The law firm Simpson Thacher & Bartlett LLP was retained by Hygo’s board to conduct the review with assistance from forensic accountants at FTI Consulting and the Brazilian law firm Demarest Advogados. The review included forensic accounting work and review of certain contracts, interviews with certain company personnel and representatives, and review of internal audit material, certain corporate card expenses and Hygo’s anti-corruption policies. The procedures undertaken by these advisors as part of the review did not identify evidence establishing bribery or other corrupt conduct involving Hygo.

Operational assets

Golar’s 50% proportionate share of Hygo’s adjusted EBITDA1 for the quarter, amounted to $15.6 million. In September, 2020, the Sergipe Power Plant incurred damage to one of its four step-up transformers, which will temporarily reduce the plant’s capacity from 1.5 Gw to 1.0 Gw until a replacement transformer is installed, expected to happen in Q2 2021. CELSE maintains insurance to cover the cost of purchasing electricity from third parties to supply its customers for up to 8.25 months in the event that CELSE is unable to supply the electricity itself due to property damage at the Sergipe Power Plant. Such insurance is subject to customary terms and conditions, including retention and standard policy exceptions, which are expected to cover the cost of any electricity that CELSE may need to purchase while the transformer is unable to generate electricity.

Reduced levels of economic activity as a result of the COVID outbreak muted Brazilian demand for electricity which therefore suppressed power prices. As a result, the Sergipe power plant was not called upon to dispatch electricity and it was not profitable to sell merchant power during Q3. The plant has not been called upon to dispatch during Q4, however consideration is being given to potential opportunities to dispatch the plant on a short-term basis for up to 1.0GW of merchant power in the coming weeks.

Small-scale LNG distribution using smaller vessels and LNG isotainers:

Hygo continues the roll-out of its small scale LNG distribution business. The appetite to gain access to cleaner cheaper LNG has not been impacted by recent events or higher LNG prices. Initial volumes are expected to be satisfied with LNG liquified by mini liquefaction solutions in the states of Bahia and Sao Paulo, which include the production of bio LNG. Additional supply points will be added from 2021 following the anticipated FID of the Barcarena and Suape terminals together with commencement of the Avenir small scale vessel charter that will link these new terminals and the FSRU Nanook to other potential markets. This small-scale vessel can carry offloaded LNG along coasts/up rivers and connect to onshore truck loading facilities where LNG can be transferred to ISO containers. These will then be distributed to industrial, commercial and residential off-takers which are underserved by traditional pipeline networks. In February 2020, Hygo entered into a strategic partnership to supply LNG volumes to BR Distribuidora (“BR”) for up to 15 years. BR and Hygo are progressing well with the formation of a joint venture to jointly facilitate the inland rollout of LNG supply to Brazil’s transportation and industrial sectors across BR’s 7,600 fuel stations and 95 supply bases.

Growth projects

1) Barcarena Terminal and Power Plant: Hygo remains committed to supply gas to the State of Para in Northern Brazil, and, subsequent to the mutual termination of the MoU with Norsk Hydro, entered into a MoU with the regulated Local Distribution Company that has the exclusive rights to distribute natural gas in the state of Pará. Operations are expected to commence in 2022, and an associated 605 MW thermal power plant (previously contracted under a 25 year PPA) from 2025.  Plans to commence construction of the terminal before year end and commence operations in 1H 2022 remain on track. Competitive quotes for the EPC contract have been received together with interest in providing attractive long term financing for the power station. A FID on the power plant component of the project is expected in first half of 2021.

2) Global Terminal Projects: In addition to several other Brazilian terminal projects, Hygo is pursuing more than fifteen terminal opportunities worldwide. Paul Hanrahan’s extensive experience and global network of contacts is expected to be particularly helpful for the prioritization of these opportunities and selection of the right business partners to work with for each.

Golar Partners (a non-consolidated affiliate of Golar LNG):

Golar Partners’ Q3 total adjusted EBITDA1was in line with Q2. A smaller decrease in swap rates during the quarter reduced the $4.5 million Q2 mark-to-market loss on the Partnerships’ interest rate swaps to a loss of $1.1 million in Q3. As a result, the Partnership reported an improved Q3 net income of $17.4 million compared to Q2 net income of $14.3 million.

Improved collection of outstanding accounts receivable combined with the reduction in distributions paid to common unitholders has also allowed the Partnership to accumulate cash, despite an increase in debt repayments. After amortization of the first $10.0 million in respect of the partnerships high yield bonds, cash and cash equivalents increased from $32.8 million at the end of Q2 to $42.3 million at the end of Q3. Subsequent to the quarter end, the Partnership has obtained credit approval from the lead banks in connection with the refinancing of the 7-vessel $800 million facility. As at September 30, 2020, $529 million was outstanding. This could be increased after a syndication exercise.

Golar Partners agreed with Hygo on August 31 to terminate the existing omnibus agreement between the two parties and enter into a new cooperation agreement. The intention of the co-operation agreement is that both parties will work together to develop hub-spoke LNG terminal solutions utilizing Golar Partners’ available asset portfolio, where those assets are technically suitable. The terms and structure of the commercial cooperation will be worked on a project by project basis given the customized nature of each potential terminal. As well as leverage the expertise of the Hygo team to develop FSRU terminals and parcel regasification demand, this agreement will, alongside normal FSRU tendering activity, increase the Partnership’s re-contracting options, and provide an opportunity to potentially earn higher returns than standard FSRU contracts in the current market. It will also allow Hygo to more quickly diversify its markets without needing to incur significant upfront CAPEX in the process.

Non-GAAP measures

In addition to disclosing financial results in accordance with U.S. generally accepted accounting principles (US GAAP), this earnings release and the associated investor presentation contains references to the non-GAAP financial measures which are included in the table below. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business and measuring our performance.

These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP. Non-GAAP measures are not uniformly defined by all companies, and may not be comparable with similarly titled measures and disclosures used by other companies. The reconciliations from these results should be carefully evaluated.

Non-GAAP measure Closest equivalent US GAAP measure Adjustments to reconcile to primary financial statements prepared under US GAAP Rationale for adjustments
Performance measures

Adjusted EBITDA
Net (loss)/income attributable to Golar LNG Limited +/- Net financial expense
+ Other non-operating expenses
+/- Income taxes
+/- Equity in net (losses)/ income of affiliates
+/- Net income attributable to non-controlling interests
+/- Unrealized loss/(gain) on oil derivative instrument
+ Depreciation and amortization
+ Impairment of long-term assets
+ Amount invoiced under sales-type lease
+/- Share of affiliates’ EBITDA (only applicable in calculating Hygo’s consolidated adjusted EBITDA)
Increases the comparability of total business performance from period to period and against the performance of other companies by excluding the results of our equity investments, removing the impact of unrealized movements on embedded derivatives and removing the impact of depreciation, financing and tax items.

Average daily TCE 
Total Operating revenues -Liquefaction services revenue
-Vessel and other management fees

-Voyage and commission expenses

The above total is then divided by calendar days less scheduled off-hire days.

Measure of the average daily net revenue performance of a vessel.

 Standard shipping industry performance measure used primarily to compare period-to-period changes in the vessel’s net revenue performance despite changes in the mix of charter types (i.e. spot charters, time charters and bareboat charters) under which the vessel may be employed between the periods.

 Assists management in making decisions regarding the deployment and utilization of its fleet and in evaluating financial performance.

Liquidity measures

Adjusted net debt
Net debt based on GAAP measures:

 Total debt (current and non-current), net of deferred finance charges

– Cash and cash equivalents

– Restricted cash and short-term deposits (current and non-current)

Net debt based on GAAP measures
+ VIE Restricted cash
+ VIE consolidation adjustment
+ Deferred finance charges
+ TRS Restricted Cash
In consolidating the lessor VIEs, we also consolidate their cash position. We reflect the lessor VIEs’ cash as “restricted cash” on our Consolidated Balance Sheet as we have no control or ability to access this cash. In calculating our adjusted net debt based on our contractual obligation, we remove the lessor VIEs’ restricted cash.

We have elected an accounting policy to show margin cash posted against our derivative positions separately to the associated MTM liability.

Management believe that these adjustments enable investors and users of our financial statements  to assess our liquidity based on our underlying contractual obligations and aids comparability with our competitors.


Contractual debt
Total debt (current and non-current), net of deferred finance charges + VIE Consolidation Adjustment
+ Deferred Finance Charges
We consolidate a number of lessor VIEs for our sale and leaseback facilities. This means that on consolidation, our contractual debt is eliminated and replaced with the lessor VIEs’ debt.

Contractual debt represents our debt obligations under our various financing arrangements before consolidating the lessor VIEs.

The measure enables investors and users of our financial statements to assess our liquidity and the split of our debt (current and non-current) based on our underlying contractual obligations. Furthermore, it aids comparability with competitors.

Reconciliations – Performance Measures (Adjusted EBITDA)

  2020 2020 2020 2019 2019
(in thousands of $) Jul-Sep Apr-Jun Jan-Sep Jul-Sep Jan-Sep
Net loss attributable to Golar LNG Limited (21,802)   (155,634)   (281,683)   (82,301)   (236,724)  
Net financial expense 18,753    12,233    105,262    39,256    110,304   
Income taxes 216    185    598    274    655   
Equity in net losses of affiliates 3,559    139,365    180,860    7,761    47,630   
Net income attributable to non-controlling interests 29,906    32,209    75,111    21,344    69,898   
Operating income/ (loss) 30,632    28,358    80,148    (13,666)   (8,237)  
Adjusted for:          
Unrealized loss/(gain) on oil derivative instrument (220)   11,810    39,400    44,170    43,420   
Depreciation and amortization 26,875    26,982    81,097    28,428    84,712   
Impairment of long-term assets —    —    —    —    41,597   
Adjusted EBITDA 57,287    67,150    200,645    58,932    161,492   

Reconciliations – Performance Measures (Average Daily TCE Rate)

  2020 2020 2019
(in thousands of $) Jul-Sep Apr-Jun Jul-Sep
  TFDEs excluding dry dock  
Total operating revenues 95,152    95,152    102,242    98,670   
Less: Liquefaction services revenue (54,524)   (54,524)   (54,524)   (54,524)  
Less: Vessel and other management fees (5,046)   (5,046)   (5,131)   (5,345)  
Time and voyage charter revenues 35,582    35,582    42,587    38,801   
Less: Steam LNG carrier time and voyage charter revenues (2,855)   —    —    —   
Less: Voyage and commission expenses (476)   (476)   (1,539)   (5,603)  
  32,251    35,106    41,048    33,198   
Calendar days less scheduled off-hire days 899    899    910    943   
Less: Steam LNG carrier and Tundra calendar days less scheduled off-hire days (163)   —    —    —   
Net calendar days less scheduled off-hire 736    —    —    —   
Average daily TCE rate (to the closest $100) 43,800    39,100    45,100    35,200   

Reconciliations – Liquidity Measures (Adjusted Net Debt)

(in thousands of $) September 30, 2020 June 30, 2020 September 30, 2019
Net debt as calculated by GAAP      
Total debt (current and non-current) net of deferred finance charges 2,541,773    2,544,865    2,554,392   
Less      
Cash and cash equivalents (76,696)   (128,661)   (250,153)  
Restricted cash and short-term deposits – current and non-current portion (162,199)   (136,535)   (375,276)  
Net debt as calculated by GAAP 2,302,878    2,279,669    1,928,963   
VIE consolidation adjustment 255,936    255,129    139,841   
VIE restricted cash 61,738    39,987    104,461   
Deferred finance charges 29,227    31,063    12,747   
TRS restricted cash (1) —    —    108,920   
Total Adjusted Net Debt 2,649,779    2,605,848    2,294,932   
Less: Golar Partners’ share of the Hilli contractual debt (397,500)   (405,750)   (430,500)  
Less: Keppel’s share of the Gimi debt (67,500)   (67,500)   —   
GLNG’s share of Adjusted Net Debt 2,184,779    2,132,598    1,864,432   

(1) Restricted cash relating to the share repurchase forward swap refers to the collateral required by the bank with whom we entered into a total return equity swap.

Reconciliations – Liquidity Measures (Contractual Net Debt)

(in thousands of $) September 30, 2020 June 30, 2020 September 30, 2019
Total debt (current and non-current) net of deferred finance charges 2,541,773    2,544,865    2,554,392   
VIE consolidation adjustments 255,936    255,129    139,841   
Deferred finance charges 29,227    31,063    12,747   
Total Contractual Debt 2,826,936    2,831,057    2,706,980   
Less: Golar Partners’ share of the Hilli contractual debt (397,500)   (405,750)   (430,500)  
Less: Keppel’s share of the Gimi debt (67,500)   (67,500)   —   
GLNG’s share of Contractual Debt 2,361,936    2,357,807    2,276,480   

Please see Appendix A for a capital repayment profile for Golar’s contractual debt.
Non-US GAAP Measures Used in Forecasting
Distribution coverage ratio: As defined in Golar LNG Partners LP most recent quarterly earnings release (Form 6-K), section “Appendix A – Non-GAAP Financial Measures and Definitions”.

Revenue Backlog: Revenue backlog is defined as the minimum contracted daily charter rate for each vessel multiplied by the number of scheduled hire days for the remaining contract term. Revenue backlog is not intended to represent EBITDA or future cashflows that will be generated from these contracts. This measure should be seen as a supplement and not a substitute for our US GAAP measures of performance.
Golar Group Contract Earnings Backlog: Golar Group Contract earnings backlog represents the Golar family’s share of contracted fee income for executed contracts less forecasted operating expenses for these contracts. In calculating forecasted operating expenditure, management has assumed that where there is an Operating Services Agreement the amount receivable under the services agreement will cover the associated operating costs, therefore revenue from operating services agreements are excluded. For contracts, which do not have a separate Operating Services Agreement management has made an assumption about operating costs based on the current run rate. The only material application of this methodology was to the Hilli Earnings backlog where we assumed operating costs of approximately $144kpd.  For consolidated subsidiaries where we do not own 100% of the share capital, management has only included our proportionate share of contract earnings. The material application of this assumption was to Gimi (70% ownership) and Hilli (44.5% of the Common Unit entitlement). No contracted fee income is included for T3 or for the Hilli oil derivative. For Golar Group Contract Earnings Backlog, the backlog of the Partnership and Hygo are included on a 100% basis using the same principals that we apply to the GLNG contract earnings backlog. The main assumption for Hygo is a USD:BRL FX rate of 4.5. For these equity accounted investments, when their contract earnings backlog actualizes, we will show our share of their earnings net of interest and tax in one line in the Income Statement “Equity in net earnings/(losses) of affiliates”. As Golar is positioned as an integrated LNG company, management believes that this metric is useful as it allows people to understand the total contracted earning backlog, based on asset performance, across the entire LNG value chain. Contract earnings backlog is not intended to represent EBITDA or future cashflows that will be generated from these projects, it also excluded items such as G&A and other non-cash accounting adjustments. This measure should be seen as a supplement and not a substitute for our US GAAP measures of performance. 

Golar LNG Limited’s pro-rata share of Golar Group Contract Earnings Backlog: GLNG’s share of Contract Earnings Backlog adjusts the Golar Group Contract Earnings Backlog to include GLNG’s proportionate share of the contract earnings backlog of our equity accounted investments. This means that only 32.2% of the Partnership’s Contracted Earnings and 50% of Hygo’s contracted earnings backlog are included. For these equity accounted investments, when their contract earnings backlog actualizes, we will show our share of their earnings net of interest and tax in one line in the Income Statement “Equity in net earnings/(losses) of affiliates”. As Golar is positioned as an integrated LNG company, management believes that this metric is useful as it allows people to understand GLNG’s share of the total contracted earning backlog, based on asset performance, across the entire LNG value chain. Contract earnings backlog is not intended to represent EBITDA or future cashflows that will be generated from these projects, it also excluded items such as G&A and other non-cash accounting adjustments. This measure should be seen as a supplement and not a substitute for our US GAAP measures of performance. 

Definitions

TFDE: Tri-fuel Diesel Electric
FSRU:
Floating Storage Regasification Unit
JKM: Japan Korea Marker
CAGR: Compound Annual Growth Rate



Forward Looking Statements

This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “will,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negative of these terms and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, Golar undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements are:

  • changes in our ability to obtain additional financing or refinancing of our existing debt, including our Term Loan facility and Margin Loan facility, each scheduled to mature in December 2020, and our 2017 convertible bonds, on acceptable terms or at all;
  • changes in our ability to comply with the covenants contained in the agreements governing our future or existing indebtedness;
  • our inability and that of our counterparty to meet our respective obligations under the Lease Operate Agreement (“LOA”) entered into in connection with the BP Greater Tortue/Ahmeyim Project (“Gimi GTA Project”);
  • continuing uncertainty resulting from potential claims from our counterparties of purported force majeure under contractual arrangements, including but not limited to our construction projects, and other contracts to which we are a party;
  • our ability to realize the expected benefits from acquisitions and investments we have made and may make in the future;
  • changes in the timeliness of the completion of the LNG Croatia (formerly known as the Golar Viking) commissioning and subsequent acceptance by the customer;
  • our ability to enter into contracts with third parties to fully utilize the Hilli Episeyo;
  • the length and severity of outbreaks of pandemics, including the ongoing worldwide outbreak of the novel coronavirus (“COVID-19”) and its impact on demand for liquefied natural gas (“LNG”) and natural gas, the timing of completion of our conversion projects, the operation of our charters, our global operations including impact to our vessel operating costs and our business in general;
  • Hygo Energy Transition Ltd.’s (“Hygo”) (formerly known as Golar Power Limited) ability to operate the Sergipe power station project and related floating storage and regasification unit (“FSRU”) contract and to execute its downstream LNG distribution and merchant power sales plans;
  • Hygo’s ability to successfully complete an initial public offering (“IPO”) of its common shares.
  • changes in our relationship with Golar LNG Partners LP (“Golar Partners”), Hygo or Avenir LNG Limited (“Avenir”) and the sustainability of any distributions they pay to us;
  • any adverse effects on us, including reputational harm, or the value of our investment in Hygo, as a result of the implication of Hygo’s former chief executive officer, Eduardo Antonello, who resigned from his position with Hygo in October 2020, in certain allegations by the Brazilian government concerning alleged improper payments made in Brazil pre-dating Mr. Antonello’s relationship with Hygo;
  • the outcome of any pending or future legal proceedings to which we are a party;
  • approval of amendments to agreements with our engineering, procurement and construction contractors and lending banks to adjust the construction and financing schedules relating to the Gimi GTA Project;
  • failure of our contract counterparties, including our joint venture co-owners, to comply with their agreements with us or other key project stakeholders;
  • changes in LNG carrier, FSRU, floating liquefaction natural gas vessel (“FLNG”), or small-scale LNG market trends, including charter rates, vessel values or technological advancements;
  • our vessel values and any future impairment charges we may incur;
  • challenges by authorities to the tax benefits we previously obtained under certain of our leasing agreements;
  • continuing volatility of commodity prices;
  • a decline or continuing weakness in the global financial markets;
  • fluctuations in currencies and interest rates;
  • our ability to close potential future sales of additional equity interests in our vessels, including the FLNG Gimi on a timely basis or at all;
  • changes in our ability to retrofit vessels as FSRUs or FLNGs, our ability to obtain financing for such conversions on acceptable terms or at all and our ability to obtain the benefits that may accrue to us as the result of such modifications;
  • changes in the supply of or demand for LNG carriers, FSRUs, FLNGs or small-scale LNG infrastructure;
  • a material decline or prolonged weakness in rates for LNG carriers, FSRUs, FLNGs or small-scale LNG infrastructure;
  • changes in the performance of the pool in which certain of our vessels operate and the performance of our joint ventures;
  • changes in trading patterns that affect the opportunities for the profitable operation of LNG carriers, FSRUs, FLNGs or small-scale LNG infrastructure;
  • changes in the supply of or demand for LNG or LNG carried by sea;
  • changes in the supply of or demand for natural gas generally or in particular regions;
  • changes in our relationships with our counterparties, including our major chartering parties;
  • changes in general domestic and international political conditions, particularly in regions where we operate;
  • changes in the availability of vessels to purchase and in the time it takes to construct new vessels or convert existing vessels;
  • failures of shipyards to comply with delivery schedules or performance specifications on a timely basis or at all;
  • changes in our ability to sell vessels to Golar Partners or Hygo;
  • changes to rules and regulations, applicable to LNG carriers, FSRUs, FLNGs or other parts of the LNG supply chain;
  • our inability to achieve successful utilization of our expanded fleet or inability to expand beyond the carriage of LNG and provision of FSRUs, FLNGs, and small-scale LNG infrastructure particularly through our innovative FLNG strategy and our joint ventures;
  • actions taken by regulatory authorities that may prohibit the access of LNG carriers, FSRUs, FLNGs or small-scale LNG vessels to various ports;
  • increases in costs, including, among other things, crew wages, insurance, provisions, repairs and maintenance; and
  • other factors listed from time to time in registration statements, reports or other materials that we have filed with or furnished to the U.S. Securities and Exchange Commission (“Commission”), including our most recent Annual Report on Form 20-F.

As a result, you are cautioned not to rely on any forward-looking statements. Actual results may differ materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.

November 30, 2020
The Board of Directors
Golar LNG Limited
Hamilton, Bermuda
Investor Questions: +44 207 063 7900
Iain Ross – CEO
Karl Fredrik Staubo – CFO
Stuart Buchanan – Head of Investor Relations

Attachment